Tag: PAD

SVS creates limb salvage-focused Frank J. Veith Lectureship

Next year’s Vascular Annual Meeting (VAM) will include a new named lecture: the Frank J. Veith Lecture, named in honor of former Society for...

New project will develop nanoparticles with imaging and medicine-delivery capabilities to...

A University of Texas at Arlington bioengineer is leading a project to develop biodegradable nanomaterials that will take pictures and deliver medicine to combat...

First results from BEST-CLI poised to reveal ‘very low’ quality of...

An analysis from the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial presented at the 2022 Vascular Annual...

Study demonstrates feasibility, effectiveness of at-home exercise therapy plus cognitive behavior...

A mobile phone-administered, home-based exercise therapy program for patients with intermittent claudication (IC) incorporating cognitive behavior therapy (CBT) was found to be feasible, with...

Researchers report higher three-year amputation and reintervention rates in Black and...

In a study of over 7,000 chronic limb-threatening ischemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention...

Open surgical bypass to distal targets at the ankle is ‘viable’...

The Vascular and Endovascular Surgical Society (VESS) Paper Session at the Vascular Annual Meeting (VAM) in Boston on Wednesday, June 15, will see Othman...

Revascularization strategy for BTK intervention should hinge on diagnostic modality, LINC...

New data provide “another argument” for the use of intravascular ultrasound (IVUS) in below-the-knee (BTK) interventions. This is according to Michael Lichtenberg, MD, from Arnsberg...

Register today for two SVS courses

Registration has opened—along with early-bird pricing—for two Society for Vascular Surgery (SVS) in-person courses in coding and reimbursement, and peripheral artery disease (PAD) skills....

Medtronic gains FDA nod for IN.PACT 018 DCB

Medtronic has announced approval from the Food and Drug Administration (FDA) for the IN.PACT 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated...

New long-term data of paclitaxel devices continue to show no increased...

New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at...

Shockwave IVL maintains ‘superiority’ to angioplasty in calcified peripheral disease at...

Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to excellent long-term outcomes...

Tissue samples show paclitaxel effect in minority of CLTI patients receiving...

Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent...

The top 10 most popular Vascular Specialist stories in March

Among the posts catching Vascular Specialist readers' eyes last month were the digital flipbook version of our March print edition, a new study looking...
alucent biomedical

Alucent Biomedical announces first patient enrolled in first-in-human natural vascular scaffolding...

Alucent Biomedical announced in a press release that it has enrolled the first patient in ACTIVATE II, an Australia-based first-in-human clinical trial to evaluate the...

Shockwave Medical announces global launch of new peripheral IVL catheter

Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both Food and Drug Administration (FDA) and...

SCVS 2022: WIfI score does not predict successful healing after transmetatarsal...

A higher initial Wound, ischemia, and foot infection (WIfI) classification score at initial presentation in chronic limb-threatening ischemia (CLTI) patients who underwent a transmetatarsal...

Potential ‘new paradigm’ in treatment of long occlusive lesions emerges

Vascular surgeon Lewis Schwartz, MD, has had an interest in biomedical engineering since very early in his career. So his involvement in the early-stage...

PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI...

Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called "no-option"...

Viabahn use in claudicants with long, complex SFA lesions ‘safe and...

Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA) lesions in...

Ra Medical Systems receives FDA approval for increased enrollment in atherectomy...

Ra Medical Systems, a medical device company focused on developing the excimer laser system to treat vascular diseases, has announced that enrollment has reached...
top 10 vascular specialist

The top 10 most popular Vascular Specialist stories in January

January’s top 10 includes “Our forever plague,” a combined editorial by Malachi Sheahan III, MD, our medical editor, on fake news and science, and...

Index atherectomy interventions for claudication ‘is associated with higher’ reintervention rates...

Atherectomy use during index peripheral vascular interventions in claudicants is associated with higher reintervention rates when compared to other technologies, a newly unveiled study...

Cook Medical receives FDA breakthrough designation for new drug-eluting stent

Cook Medical has received Breakthrough Device designation from the Food and Drug Administration (FDA) on a new drug-eluting stent (DES) for below the knee...

ISET 2022 audience hears latest data on endovascular therapies

At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results...

CSI announces development of IVL technology for the treatment of PAD

Cardiovascular Systems (CSI) recently announced that it has made significant progress towards the commercialization of its intravascular lithotripsy (IVL) system for the treatment of...

SVS PAD course postponed

The new Society for Vascular Surgery (SVS) Peripheral Arterial Disease (PAD) Skills Course has been postponed amid the COVID-19 pandemic recent surge in cases,...

Vascular Specialist–December 2021

In this issue: *This issue went to press before Congress moved to address cuts to Medicare due to kick in Jan. 1, 2022. "Countdown to...

Smoking status ‘should not deter nor delay’ endovascular intervention in femoropopliteal...

Smoking does not seem to affect reocclusion rates, interval to reintervention and the total number of interventions in peripheral arterial disease (PAD) patients with...

Learn by doing at February SVS PAD workshop

The Society for Vascular Surgery (SVS) Peripheral Arterial Disease (PAD) Workshop in February will feature four hours of hands-on surgical skills training, on 10...

Rise in cardiovascular disease, vascular surgeon burnout presents a public health...

Cases of cardiovascular disease are rising across the U.S., with large disparities seen in ethnic groups and poorer geographical areas. In combination with increased...

Endologix announces completion of enrollment in TORUS 2 study for PAD...

Endologix has completed enrollment in the TORUS 2 investigational device exemption (IDE) clinical study in the U.S., a press release reports. The TORUS 2 study...

Prediabetes screening: ‘Target of reducing disparities should be geared towards advocacy’

On Aug. 24, the United States Preventive Services Task Force (USPSTF) published the newly updated recommendations regarding screening for prediabetes and type-2 diabetes mellitus.1,2...

First patient enrolled in Disrupt BTK II study for long, calcified,...

Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the Shockwave...

Take advantage of SVS diabetes resources

November is National Diabetes Month. The Society for Vascular Surgery (SVS) has many resources to help its members educate their patients and families and...
PAD

Hispanic adults with PAD access inpatient care most often via the...

Hispanic adults hospitalized for treatment of symptoms of peripheral arterial disease (PAD) were more likely to access this care by going to the emergency...

Philips announces large-scale study outcomes on use of IVUS in peripheral...

Royal Philips has announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health...

WVS 2021: Western Vascular Society names new president-elect

University of Southern California (USC) vascular chief Vincent Rowe, MD, took over as the new president of the Western Vascular Society (WVS)—with University of...

The top 10 most popular Vascular Specialist stories in September

Five-year data from the ACST-2 trial comparing carotid endarterectomy and carotid artery stenting, a report from the Crawford Forum at the 2021 Vascular Annual...

PROMISE I 24-month results ‘validate the benefits of the LimFlow system’

LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for...

One-year results show ‘superior’ primary patency rate for Eluvia DES compared...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia...

VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel...

An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and...

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

VIVA 2021: Consensus established for appropriate use of IVUS in peripheral...

A worldwide committee of 40 cross-specialty medical experts achieved what was hailed as the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS)...

Save the date for new PAD skills workshop

September is National PAD Awareness Month, and the Society for Vascular Surgery (SVS) will spend the month not only calling attention to causes and...

First patient enrolled in BIONETIC-I study of iliac artery treatment

Biotronik has announced the first patient enrollment in the BIONETIC-I study of the safety and efficacy of the Dynetic-35 cobalt chromium balloon-expandable stent system...

‘Proceed cautiously in use of DCBs in CLTI patients with advanced...

The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial...

European launch: Medtronic receives CE mark for 200mm and 250mm IN.PACT...

Medtronic has announced the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs) following CE mark approval. The product is intended to treat long...

PAD: R3 Vascular reports ‘successful initiation’ of first-in-human study of bioresorbable...

Medical device developer R3 Vascular has reported the "successful initiation" of a first-in-human clinical study evaluating the technical and clinical performance of its Magnitude...

Physicians draw attention to Medicare cuts as PAD Awareness Month kicks...

A coalition of physicians and other interested parties focused on peripheral arterial disease (PAD) has called on Congress and the Centers for Medicare and...

Females were 30% less likely to undergo surgery for PAD, national...

A review of more than 1 million patients receiving vascular surgery over a 16-year period identified significant sex-related disparities in the treatment of abdominal...

USPSTF expands screening recommendation for prediabetes, type-2 diabetes to adults aged...

The United States Preventive Services Task Force (USPSTF) has issued an updated recommendation statement suggesting clinicians screen for prediabetes and type-2 diabetes in overweight...

VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism

A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional...
x-ray image below knee amputation or BKA amputation

Amputation rates higher for people with PAD who are poor or...

Poverty and Black race were associated with higher rates of lower-leg amputation among people with peripheral arterial disease (PAD) who live in metropolitan areas, according to new...

Vascular Quality Initiative launches ‘My PAD’ pilot

The Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) has created “My PAD,” a pilot program for collecting patient-reported outcomes (PROs) from patients...

FDA approves expanded PAD indication for rivaroxaban plus aspirin

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease...

Veterans with claudication who undergo revascularization ‘significantly more likely to have...

Patients within the Veterans Affairs Administration healthcare system who underwent an intervention for intermittent claudication (IC) were consistently at three-to-four times greater risk of...

‘Let’s move on to solutions,’ keynote speaker tells diversity, equity and...

Lee Kirksey, MD, issued an unapologetic apology of sorts at the outset of his discussion of diversity, equity and inclusion (DEI) issues. “If I...

Colombian researchers report positive 24-month results for VenoValve

Promising two-year results for an emerging potential prosthetic venous valve replacement—which is about to commence a U.S. pivotal trial—were announced at the Vascular Annual...

Research letter highlights low adoption of supervised exercise therapy for PAD

A research letter published in Circulation: Cardiovascular Quality and Outcomes highlights a “very low” utilization of supervised exercise therapy (SET) in symptomatic peripheral arterial disease (PAD) patients...

VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower-extremity bypass...

“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev,...

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment

MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee...

VAM: Industry-sponsored symposia

Industry-sponsored symposia at the Vascular Annual Meeting (VAM) will be presented Wednesday and Thursday evenings and at three breakfast sessions taking place Thursday morning....

Study of amputees finds referral for prosthetics to be an independent...

Prosthetic referral was an independent predictor of long-term survival among patients who had undergone lower-extremity amputation, new findings set to be published in the...

AHA publishes updated scientific statement on PAD

The American Heart Association (AHA) has released a new scientific statement on lower extremity peripheral arterial disease (PAD), focusing on contemporary epidemiology, management gaps, and future directions. The...

Special session on diversity enters VAM agenda

Over the course of more than a year, diversity, equity and inclusion (DEI) have been brought into sharp focus by a compendium of events...

The year in COVID: VAM to feature 10 talks probing pandemic-related...

After nearly 18 months of life dominated by a worldwide pandemic—one that canceled the 2020 Vascular Annual Meeting (VAM)—VAM 2021 highlights several aspects of...

Introducing patient-reported outcomes into the VQI

Vascular specialists have long recognized that there is more to the treatment of peripheral arterial disease (PAD) than the immediate procedural success and early...

Fighting the good fight: The case for multidisciplinary limb salvage in...

Dramatic increases in rates of diabetes—particularly among Black females—through 2060 underscore the importance of a multidisciplinary team approach to limb salvage, according to Vincent...

Fempop bypass shows reintervention benefit over endovascular therapy for advanced premature...

Femoropopliteal bypass is associated with decreased reinterventions at one year compared to endovascular therapy in patients with advanced premature peripheral arterial disease (PAD). This is...

The top 10 most popular Vascular Specialist stories in May

A pointed letter aimed at electronic health record (EHR) behemoth Epic, an argument in favor of endovascular treatment of ruptured abdominal aortic aneurysms (rAAAs)...

Pearls of wisdom for interns

It’s June and, in less than a month, a swarm of new faces, and freshly minted MDs and DOs will descend upon most academic...

Philips announces positive two-year data from TOBA II BTK clinical trial

Royal Philips recently announced positive two-year results from the TOBA (Tack optimized balloon angioplasty) II below-the-knee (BTK) clinical trial. The data show the Philips Tack endovascular...

Stenting found to be superior to atherectomy, balloon angioplasty in reducing...

Stenting reduced mortality risk in patients undergoing interventions for peripheral arterial disease (PAD) by more than 30% when compared to plain balloon angioplasty, and...

One-year results from PROMISE I study of LimFlow system in ‘no-option’...

Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been...

ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices

Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky,...

ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in...

Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease...

Intermittent claudication and exercise therapy: A poor SET-up

Many of you may have already heard about the controversial Comparative Billing Reports (CBRs) that have been received by some of our vascular surgery...

The top 10 most popular stories from April

Our April cover story on the links between electronic health records (EHRs) and physician burnout, the continuing problem of manels (or all-male speaking panels)...

MicroStent to treat PAD below the knee receives FDA breakthrough device...

Micro Medical Solutions (MMS) recently revealed Food and Drug Administration (FDA) breakthrough device designation for its MicroStent vascular stent. This novel technology is designed...

Interventions associated with ‘poor’ two-year relief of intermittent claudication symptoms

Peripheral vascular interventions for intermittent claudication were linked to "poor" two-year relief of symptoms in the Vascular Quality Initiative (VQI) database, a new study...

SoundBite peripheral crossing system gains FDA approval

Soundbite Medical Solutions has announced Food and Drug Administration (FDA) 510(k) approval for the SoundBite crossing system—Peripheral (SCS-P) with the 0.014” active wire (14P). The...

PAD: Endologix acquires PQ Bypass

Endologix recently announced completing the acquisition of PQ Bypass, a medical technology company pioneering a first-of-its-kind technology that addresses severe peripheral arterial disease (PAD). PQ...

Lessons in PAD care from VA vascular surgeons

The care of patients with peripheral arterial disease (PAD) is challenging and costly. Every practicing vascular surgeon knows that when patients present with ulcerations,...

Surmodics announces first patient uses of two Sublime radial access platform...

Surmodics recently announced the successful first uses in patients for two devices within its Sublime radial access platform: the Sublime radial access guide sheath and...

Study identifies ‘critical need’ for guidelines on appropriate use of atherectomy

No data currently exist to support the use of atherectomy over other procedures for the treatment of peripheral arterial disease (PAD), and the healthcare...

SVS SET: PAD patient walks away from pain

Ice, cold and snow make it tough to walk outside in Lansing, Michigan, right now. So, jokes Doug Giller, he is wearing a path...

Coaches ‘integral’ to SVS SET app program

“A good coach will make his players see what they can be rather than what they are.” Those are words ascribed to football coach...

Supervised Exercise Therapy: There’s an app for that

Call it timing on several fronts, each part coming together for the benefit of patients with peripheral arterial disease (PAD). Included in the mix was...

Postmarket study of sirolimus-eluting balloon enrolls first patient

MedAlliance has announced enrollment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon Selution SLR for the treatment...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

How to succeed in vascular surgery: A guide for the aspiring...

Disclaimer: The views expressed here do not reflect those of Mayo Clinic, the Society for Vascular Surgery, Vascular Specialist, or even the author, for...

Walking can relieve leg pain in people with PAD

Exercise can play an important role in treating peripheral arterial disease (PAD), a recent review by Amy Harwood, PhD, from the Centre for Sport and...

Target 2021: SVS councils and committees drill down on key goals...

While there is little doubt the pandemic has impacted each vascular surgeon and the SVS as a Society in numerous ways, the commitment and...

‘Successful’ first-in-human use of the Efemoral scaffold system announced

Efemoral Medical has announced the first-in-human (FIH) use of the company’s Efemoral Vascular scaffold system (EVSS) with FlexStepv technology in the EFEMORAL I FIH...

WIfI score found to be accurate across racial groups

The wound, ischemia and foot infection (WIfI) score is as accurate a predictor of risk for limb loss in Black people as it is...

Revascularization ‘improves’ walking performance in claudicating PAD patients 

Revascularization of the lower extremity improves hemodynamics, walking performance, quality of life and calf-muscle pathology in claudicating patients with peripheral arterial disease (PAD), researchers...

VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients...

In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population...

Previously described patient-centered clinical success measure after revascularization for diabetic foot...

Patient-centered clinical success after lower-extremity revascularization for people with diabetic foot wounds was achieved among 63% of patients in a new analysis—but researchers suggest...

Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to...

The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray,...

Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes...

Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device...

Utilize new SVS Branding Toolkit

The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and...

Janssen applies to FDA for new indication to expand use of...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug...

New analysis finds DCBs lead to greater four-year survival after fempop...

Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation...

Hodgson: Bringing appropriateness into sharper focus

In 2019, Kim Hodgson, MD, kicked off his presidential year by placing appropriateness and quality of care under the microscope. His turn organizing the...

Vascular Specialist–October 2020

In this issue: Special interview: Kim Hodgson, MD, discusses his SVS presidency, his appropriateness-in-care agenda, the new SVS SET app, and his post-presidential priorities...

VA system delivers high quality services for veterans

Vascular surgery in the Veterans Health Administration has always been a robust service, developing into a mature specialty around the time of the Vietnam...

‘No signal of increased risk of long-term mortality’ with paclitaxel-coated Luminor...

An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two years...

Disproportionately more women are affected by depression when pursuing specialty PAD...

A disproportionately higher percentage of women are affected by depressive symptoms when they seek specialty care for new or worsening peripheral arterial disease (PAD)...

High level of heterogeneity found in randomized PAD trial antithrombotic regimens

A recent systematic review showed that randomized trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their...

Diversity, equity and inclusion: Disparities in medicine and vascular surgery

Recent months have yielded a conversation on systemic racism perhaps unlike any other before. We’ve learned about how it manifests across society, how it...

‘If I had gone along the path advised, I would never...

Some of the formative educational experiences described by Olamide Alabi, MD, read like textbook examples of the subtleties many see as baked into U.S....

Doubted as a doctor during mid-flight medical emergency and once asked:...

In a vascular surgery career spanning 20 years, Vincent Rowe, MD, has seen it all: Tending to patients at bedside, the vascular surgical services...

‘Casting a wider net’ when researching genetic and molecular factors of...

For vascular surgeon and research scientist Elsie Gyang Ross, MD, the world of data science might hold some of the answers to the kind...

‘Improving disparities in healthcare is not a matter of slapping some...

Andrew Gonzalez, MD, had a heart for underserved and under- resourced communities embedded early. The son of a pediatric hematologist mother who worked at...

Black patients in areas with lowest PAD rates disproportionally at higher...

It’s among the most topical areas of discussion in current U.S. cultural life: Black people face disparities in terms of healthcare outcomes. And the...

SVN to host virtual annual meeting July 15

The Society for Vascular Nursing (SVN) 38th Annual Conference—a virtual meeting—will be held from 6 to 9:30 p.m. Central Daylight Time Wednesday, July 15. In...

International Lecture: Endovascular colossus discusses new PAD therapy

A new therapy of hydration and oncotic pressure of plasma helped 100% of certain elderly peripheral artery disease (PAD) patients in terms of pain,...

SVS pilots SET app for peripheral artery disease patients

Doctor-prescribed and -supervised exercise therapy is going digital. The Society for Vascular Surgery (SVS) will begin piloting a ground-breaking app for Supervised Exercise Therapy...

SVS in transition: A look back, a look ahead

Each Society for Vascular Surgery (SVS) president wishes for a memorable annual meeting, outgoing SVS president Kim Hodgson, MD, noted during his State of...

TOBA III clinical trial results published

Intact Vascular has announced the peer-reviewed publication of its Tack optimized balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery. The multi-center, single-arm,...

Technology drives vascular future

Decades ago, “picture” phones were an idea straight out of science fiction. As the saying goes, the future is now. FaceTime and Skype are...

Quality: Global Vascular Guidelines pocket guide coming soon

The Global Vascular Guidelines (GVG), extensively researched and written by an international committee of leading vascular experts, will soon be available as a pocket...

Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or...

“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence...

Combining aspirin with rivaroxaban reduces risk equally in presence or absence...

In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular and peripheral endpoints in patients...

Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization

Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of...